食管胃结合部癌靶向治疗的研究进展

Progress of targeted therapy for esophagogastric junction cancer

食管胃结合部(EGJ)癌是一类较特殊的消化道肿瘤,且患者预后往往不良,靶向药物在这种疾病中的使用越来越得到重视。文章通过结合EGJ癌的靶向治疗试验对针对人类表皮生长因子受体2(HER2)、血管内皮生长因子(VEGF)、表皮生长因子受体(EGFR)、MET、成纤维细胞生长因子受体2(FGFR2)等靶点的药物及疗效进行归纳,并对MTOR、Claudin 18.2、PARP抑制剂、免疫治疗等新的治疗方法进行总结。

Esophagogastric junction cancer(EGJ)is a special type of digestive tract tumor.The poor prognosis of patients with esophageal and gastric cancer has led to an increasing emphasis on the use of targeted drugs in this disease.This article summarizes and supplements the drugs and effects against human epidermal growth factor receptor 2(HER2),vascular endothelial growth factor(VEGF),epidermal growth factor receptor(EGFR),MET,fibroblast growth factor receptor 2(FGFR2)and other targets by combining targeted therapy with EGJ cancer,and then reviews new treatment methods such as MTOR,Claudin 18.2,PARP inhibitor,and immunotherapy.